SciELO - Scientific Electronic Library Online

 
vol.28 issue4Diabetes melutus associated with pentamidine isethionate in diffuse cutaneous leishmaniasisAusência de lesão cardíaca atribuível ao Trypanosoma cruzi, pelo menos após dezessete anos de decurso de doença de Chagas transfusional author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista da Sociedade Brasileira de Medicina Tropical

Print version ISSN 0037-8682

Rev. Soc. Bras. Med. Trop. vol.28 no.4 Uberaba Oct./Dec. 1995

http://dx.doi.org/10.1590/S0037-86821995000400016 

RELATO DE CASO

 

Claritromicina associada com pirímetamina na toxoplasmose cerebral - relato de dois casos

 

 

Marcos Olivicr Dalston; Walter Tavares; Ana Ricordi Bazin; Miriam Dumas Hahn; Alair Augusto S. Damas dos Santos; Teimo Pimentel; Jurema Nunes Mello

Endereço para correspondência

 

 


RESUMO

Os autores relatam a resposta terapêutica da claritromicina associada com pirímetamina em dois casos de toxoplasmose cerebral ocorridos em pacientes com Síndrome de Imunodeficiência Adquirida (SIDA). Nos dois casos o diagnóstico foi presuntivo, baseando-se nas manifestações clínicas e na presença de lesões expansivas hipercaptantes detectadas na tomografia computadorizada (TC) de crânio. Em ambos os casos, observou-se exantema com o uso da sulfadiazina e da clindamicina, razão pela qual tais medicamentos foram substituídos pela claritromicina (1,5 a 2g/dia) associada à pirímetamina (25mg/dia). A resposta terapêutica foi favorável nos dois casos com melhora das manifestações neurológicas e dos achados neurorradiológicos. Os autores sugerem que a associação claritromicina com pirímetamina pode ser útil como opção terapêutica na toxoplasmose cerebral em pacientes com SIDA que apresentam intolerância ou outra contra-indicação ao emprego das sulfonamidas.

Palavras-chave: Claritromicina. Toxoplasmose cerebral. SIDA.


ABSTRACT

The authors report the use and tbe outcome of claritromycin associated with pyrimethamine in the treatment of toxoplasma encephalites in two patients with AIDS. Both patients had the diagnosis stablished on clinical grounds, positive sorology (IgG) for toxoplasmosis and computed-tomographic (CT) scan of the brain showing lesions consistent with T. gondii encephalitis. The two patients were initially treated with pyrimethamine and sulfadiazme, which was changed to clindamycin due to allergic reactions. These reactions (skin rash) occurred with clindamycin as well and the patients were treated with claritromycin and pyrimethamine. The scheduled regimens were 1.5 to 2g of clarithromycin plus 25mg of pyrimethamine. The clinical response was very good in both cases with regression of neurologic signs and encephalitic abnormalities observed on CT scan. The authors suggest that clarithromycin associated with pyrimethamine may be an alternative treatment for toxoplasmosis in AIDS patients, who cannot receive or tolerate sulfa treatment.

Keyworks: Clarithromycin. Cerebral toxoplasmosis. AIDS.


 

 

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

 

 

REFERÊNCIAS BIBLIOGRÁFICAS

1. Araujo FG, Prokocimer P, Lin T, Remington JS. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrobial Agents and Chemotherapy 36:2454-2457,1992.         [ Links ]

2. Chang HR, Pechére HCF. In vitro effects of four macrolides (Roxithromycin, Spiramycin, Azithromycin [CP-62.993], and A-56268 on Toxoplasma gondii. Antimicrobial Agents Chemotherapy 32:524-528,1988.         [ Links ]

3. Chimelli L, Rosemberg S, Hahn MD, Lopes MBS, Netto MB. Pathology of the central nervous system in patients infected with the human immunodeficiency virus (HIV): a report of 252 autopsy cases from Brazil. Neuropathology and Applied Neurobiology 18:478-488,1992.         [ Links ]

4. Cohn JA, McMeeking A, Cohen W, Jacobs J, Holzman RS. Evaluation of the policy of empiric treatment of suspected toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. The American Journal Medicine 86:521-527,1989.         [ Links ]

5. Dantiemann BR, Israelski DM, Remington JS. Treatment of toxoplasmic encephalitis with intravenous clindamycin. Archives of Internal Medicine 148:2477-2482,1988.         [ Links ]

6. Fernandez-Martin J, Leport C, Morlat P, Meyohas MC, Chauvin JP, Vilde JL. Pyrimethamine- clarithromycin combination for therapy of acute toxoplasma, encephalitis in patients with AIDS. Antimicrobial Agents Chemotherapy 35:2049- 2052,1991.         [ Links ]

7. Haverkos HW. Assessment of therapy for toxoplasma encephalitis.TheTE study group.The American Journal of Medicine 82:907-914,1987.         [ Links ]

8. Navia BA, Petito CK, Gold JWM, Cho ES, Jordan BD, Price RN. Cerebral toxoplasmosis complicating the acquire immune deficiency syndrome: clinical and neuropathological findings in 27 patients. Annals Neurology 19:224- 238,1986.         [ Links ]

9. Ruf B, Schiirmann D, Pohle HD. Failure of clarithromycin in preventing toxoplasmic encephalitis in AIDS patients. Journal of Acquired Imune Deficiency Syndromes 5:530-531,1992.         [ Links ]

10. Snider WD, Simpson DM, Nielsen S, Gold JWM, Metroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Annals Neurology 14:403-418,1983.         [ Links ]

11. Wong B, Gold JWM, Brown AE, Lange M, Fried R, Grieco M, Mildvan D, Giron J, Tapper ML, Lerner CW, Armstrong D. Central-nervous-system toxoplasmosis in homosexual men and parenteral drug abusers. Annals of Internal Medicine 100:36-42,1984.         [ Links ]

 

 

Recebido para publicação em 07/11/94.

 

 

Disciplina de Doenças Infecciosas e Parasitárias do Hospital Universitário Antonio Pedro e Departamento de Medicina Clínica, Faculdade de Medicina da Universidade Federal Fluminense, Niterói, RJ.

 

 

Endereço para correspondência:
Dr. Marcos Olivier Dalston
R. Luiz Erthal 31, Qadra 68, Piratininga, 24350-050
Niterói, RJ.

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License